Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Rhythm Pharmaceuticals, Inc. (RYTM : NSDQ)
 
 • Company Description   
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.

Number of Employees: 140

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.27 Daily Weekly Monthly
20 Day Moving Average: 521,539 shares
Shares Outstanding: 50.39 (millions)
Market Capitalization: $164.79 (millions)
Beta: 1.69
52 Week High: $22.48
52 Week Low: $3.04
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -59.23% -55.36%
12 Week -55.99% -50.54%
Year To Date -67.23% -59.97%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
222 BERKELEY STREET 12TH FLOOR
-
BOSTON,MA 02116
USA
ph: 857-264-4280
fax: 857-264-4299
hannah.deresiewicz@sternir.com http://www.rhythmtx.com
 
 • General Corporate Information   
Officers
David P. Meeker - Chief Executive Officer; Director; Chairman
Hunter Smith - Chief Financial Officer
William T. Roberts - Chief Accounting Officer
Edward T. Mathers - Director
Stuart Arbuckle - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 76243J105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 50.39
Most Recent Split Date: (:1)
Beta: 1.69
Market Capitalization: $164.79 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.09 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.70
Price/Cash Flow: -
Price / Sales: 35.69
EPS Growth
vs. Year Ago Period: -216.67%
vs. Previous Quarter: -23.53%
Sales Growth
vs. Year Ago Period: 4,180.00%
vs. Previous Quarter: -17.56%
ROE
03/31/22 - -55.66
12/31/21 - -20.80
09/30/21 - -20.19
ROA
03/31/22 - -48.91
12/31/21 - -18.61
09/30/21 - -18.22
Current Ratio
03/31/22 - 5.36
12/31/21 - 7.10
09/30/21 - 14.30
Quick Ratio
03/31/22 - 5.36
12/31/21 - 7.10
09/30/21 - 14.30
Operating Margin
03/31/22 - -3,598.16
12/31/21 - -2,207.13
09/30/21 - -
Net Margin
03/31/22 - -3,598.16
12/31/21 - -2,207.13
09/30/21 - -
Pre-Tax Margin
03/31/22 - -4,074.77
12/31/21 - -2,207.10
09/30/21 - -4,013.01
Book Value
03/31/22 - 4.68
12/31/21 - 5.65
09/30/21 - 6.41
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©